BIX 02565
目录号 : GC12982A RSK2 inhibitor with multiple off target effects
Cas No.:1311367-27-7
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Kinase experiment [1]: | |
Determination of IC50 at RSK2 |
Compounds were assessed for their ability to inhibit the phosphorylation of a substrate peptide by RSK2 as described previously (Boyer et al., 2011). In brief, human RSK2 protein (Invitrogen, Carlsbad, CA) was used to measure kinase activity utilizing Kinase GloPlus (Promega, Madison, WI) that uses a luciferin-luciferase based detection reagent to quantify residual ATP. The relative light unit signal was measured on an LJL Analyst (Molecular Devices, Sunnyvale, CA) in luminescence mode using 384 aperture; relative light unit signals were converted to percentage of control; the IC50 was fitted to a standard four-parameter logistic equation. |
Animal experiment [1]: | |
Animal models |
Rats model |
Dosage form |
1, 3, 10, 30, 100, and 300 mg/kg, p.o. once per day for 4 days |
Applications |
BIX 02565 (1, 3, and 10 mg/kg) elicited decreases in both mean arterial pressure and heart rate in anesthetized rats. Moreover, BIX 02565 (30, 100, and 300 mg/kg) also induced concentration-dependent decreases in mean arterial pressure (MAP) after each daily oral dose in telemetry-instrumented conscious rats. |
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
References: 1. Fryer, R. M., Muthukumarana, A., Chen, R. R., Smith, J. D., Mazurek, S. N., Harrington, K. E., Dinallo, R. M., Burke, J., DiCapua, F. M., Guo, X., Kirrane, T. M., Snow, R. J., Zhang, Y., Soleymanzadeh, F., Madwed, J. B., Kashem, M. A., Kugler, S. Z., O'Neill, M. M., Harrison, P. C., Reinhart, G. A. and Boyer, S. J. (2012) Mitigation of off-target adrenergic binding and effects on cardiovascular function in the discovery of novel ribosomal S6 kinase 2 inhibitors. J Pharmacol Exp Ther. 340, 492-500 |
BIX 02565 is a novel inhibitor of ribosomal S6 kinase 2 with IC50 value of 1 nM [1].
Ribosomal S6 kinase (RSK) is a Na/H exchanger (NHE) -activating factor and is important for pH maintenance during the early phase of cellular stress. While, NHE activation leads to Ca2+ overload and cardiac hypertrophy over longer periods [2].
BIX 02565 is a novel RSK2 inhibitor. Also, BIX 02565 inhibited adrenergic ɑ1A-, ɑ1B-, ɑ1D-, ɑ2A-, β2- and imidazoline I2 receptors with IC50 values ranging from 0.052 to 1.820 μM. These receptors played important roles in the regulation of vascular tone and cardiac function [2]. Also, BIX 02565 inhibited LRRK2 and PRKD1 with IC50 values of 16 and 35 nM [1].
In the rat CV screen, BIX 02565 (1, 3 and 10 mg/kg) significantly decreased heart rate (-93 +13 beats/min) and mean arterial pressure (MAP: to -65 +6 mm Hg below baseline). In telemetry-instrumented rats, BIX 02565 (30, 100 and 300 mg/kg for 4 days) reduced MAP (to -39 + 4 mm Hg) in a concentration-dependent way [2].
References:
[1]. Kirrane TM, Boyer SJ, Burke J, et al. Indole RSK inhibitors. Part 2: optimization of cell potency and kinase selectivity. Bioorg Med Chem Lett, 2012, 22(1): 738-742.
[2]. Fryer RM, Muthukumarana A, Chen RR, et al. Mitigation of off-target adrenergic binding and effects on cardiovascular function in the discovery of novel ribosomal S6 kinase 2 inhibitors. J Pharmacol Exp Ther, 2012, 340(3): 492-500.
Cas No. | 1311367-27-7 | SDF | |
Canonical SMILES | C[C@](N12)([H])CCNC(C2=CC3=C1C=C(/C(O)=N/C4=NC5=CC=CC=C5N4CCCN(C)C)C=C3)=O | ||
分子式 | C26H30N6O2 | 分子量 | 458.56 |
溶解度 | ≥ 22.95mg/mL in DMSO | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.1807 mL | 10.9037 mL | 21.8074 mL |
5 mM | 0.4361 mL | 2.1807 mL | 4.3615 mL |
10 mM | 0.2181 mL | 1.0904 mL | 2.1807 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。